본문 바로가기

business

Pipeline

Autologous Immunotherapy

SNK01-US01 Clinical study in the U.S.

  • Target disease : Combination Therapy of Refractory Cancer + Pembrolizumab or Avelumab
  • Trial No. : NCT03941262 Learn more
  • Discovery
  • Preclinical
  • Phase I
  • Phase II

SNK01-N12a Clinical study in Korea

  • Target disease : Combination therapy of non-small cell lung cancer + pembrolizumab
  • Trial No. : KCT0003463 Learn more
  • Discovery
  • Preclinical
  • Phase I
  • Phase II

SNK01-102 Clinical study in the U.S.

  • Target disease : Combination Therapy of HER2-positive or EGFR-positive Cancers + Trastuzumab or Cetuximab
  • Trial No. : NCT04464967 Learn more
  • Discovery
  • Preclinical
  • Phase I
  • Phase II

4) Clinical study in the U.S.

  • Target disease : Combination Therapy of EGFR-positive Cancer + AFM24
  • Discovery
  • Preclinical
  • Phase I
  • Phase II

SNK01-MX03 Clinical study in Mexico

  • Target disease : Psoriasis (autoimmune disease)
  • Trial No. : NCT03894579 Learn more
  • Discovery
  • Preclinical
  • Phase I
  • Phase II

SNK01-MX04 Clinical study in Mexico

  • Target disease : Mild Cognitive Impairment (MCI) and Alzheimer’s Disease (AD)
  • Discovery
  • Preclinical
  • Phase I
  • Phase II

Allogenic Immunotherapy

  • Discovery
  • Preclinical
  • Phase I
  • Phase II

CAR-NK

  • Discovery
  • Preclinical
  • Phase I
  • Phase II


Move to Top